OncoMed Pharma (OMED) Misses Q1 EPS by 14c

OncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.49), $0.14 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $15.35 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c